Share Name Share Symbol Market Type Share ISIN Share Description
Integumen Plc LSE:SKIN London Ordinary Share GB00BYWJ6269 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.055 -2.99% 1.785 2,738,890 12:34:40
Bid Price Offer Price High Price Low Price Open Price
1.77 1.80 1.84 1.765 1.84
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
  0.27 -2.12 1.00 1.8 17
Last Trade Time Trade Type Trade Size Trade Price Currency
15:50:18 O 13,705 1.795 GBX

Integumen (SKIN) Latest News

More Integumen News
Integumen Takeover Rumours

Integumen (SKIN) Share Charts

1 Year Integumen Chart

1 Year Integumen Chart

1 Month Integumen Chart

1 Month Integumen Chart

Intraday Integumen Chart

Intraday Integumen Chart

Integumen (SKIN) Discussions and Chat

Integumen Forums and Chat

Date Time Title Posts
22/10/201921:50Integumen - Skin in the Game7,420
12/7/201907:51Integumen82
26/2/201914:05True Judaism a means to a co-existance with Non-Jews9
06/4/201711:44Skin in the Game2

Add a New Thread

Integumen (SKIN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-10-22 14:50:191.8013,705246.00O
2019-10-22 13:44:311.77450,0007,965.90O
2019-10-22 13:30:281.8051,777929.40O
2019-10-22 12:00:481.77275,0004,873.28O
2019-10-22 11:44:111.8027,810500.00O
View all Integumen trades in real-time

Integumen (SKIN) Top Chat Posts

DateSubject
22/10/2019
09:20
Integumen Daily Update: Integumen Plc is listed in the sector of the London Stock Exchange with ticker SKIN. The last closing price for Integumen was 1.84p.
Integumen Plc has a 4 week average price of 1.61p and a 12 week average price of 1.54p.
The 1 year high share price is 2.61p while the 1 year low share price is currently 0.40p.
There are currently 977,986,902 shares in issue and the average daily traded volume is 3,331,506 shares. The market capitalisation of Integumen Plc is £17,457,066.20.
07/10/2019
07:43
johnwise: Integumen PLC Labskin signs multi-year service agreement 07/10/2019 7:00am UK Regulatory (RNS & others) RNS Number : 8585O Integumen has signed multi-year agreements with two Top 10 global cosmetic companies for recurring LabskinAI services, with initial aggregate low six-figure payments already received. Under the framework agreements being rolled out, R&D teams in US, Asia and the EU will connect and collaborate with the LabskinAI virtual lab. This will involve testing existing products and new product development on LabskinAI, making full use of our healthy and diseased living skin models, and analysed by the LabskinAI platform. https://uk.advfn.com/stock-market/london/integumen-SKIN/share-news/Integumen-PLC-Labskin-signs-multi-year-service-agr/80870778
02/8/2019
08:48
homeboy: just to remind people - sorry lemmings this is the business model here imvhaebmo - "how its likely to pan out here - they'll put out some rns's to show progress, then they'll raise money again - dilution it'll be for some identified bolt on business probably owned by someone they know who'll do well out of being bought out. 20m skin now becomes 40m skin, but share price still near 2p thanks to the dilution, then they'll find another bolt on business and dilute again one day, skin is worth 100m, but strangely the share price is still at 2p, thanks to buying in market cap at the expense of dilutive fund raising, at a future point, skin has a 100 to 1 consolidation 2p now becomes 2 quid they then say, since we took over skin has been a major success, we built a 5m quid business into a 100m quid business, and the share price has grown to 2 quid, lol but no one makes any money except those whose businesses who were bought out. lol"
31/7/2019
08:09
soultrading: Another good update. Share price will have to move up soon or later. Wed, 31st Jul 2019 07:00 RNS Number : 2771H Integumen PLC 31 July 2019 AIM share code: SKIN 31 July 2019 Integumen PLC ("Integumen" or "Company") AGM - Trading Update Integumen issues the following update on current trading and outlook for the year, to coincide with the Company's Annual General Meeting taking place later today. Outlook The current level of pipeline activity continues to be significantly higher than the Company has experienced in the past. This has resulted in a requirement to increase the laboratory size by 100% in two announced upgrades in the last 12 months. Demand continues to increase for the company's products and services. The Board is satisfied that it is meeting its objective of increasing the average revenue per client as it evolves into a multiple revenue stream product and services company for skin related diseases, treatments and therapies. Post Year-End 2018 commercial activity: · After increased demand for services: o Labskin York, UK laboratory increased by 40% in H1; o Investment of £400,000 for hi-tech laboratory equipment; o Labskin York, UK laboratory space will increase by a further 50% in Q3 2019; o Offices opened in Cork, Ireland for IT, AI infrastructure support and global sales; · Four Blue-Chip (US and EU) client agreements signed for test services on household name soap and cosmetic brands to comply with EU Directive 745/2013 Rule 21 and EU 655/2013 · Labskin human volunteer bacteria cloning service launched that allows Integumen to enter the clinical trial and medical device sector. · First external development facility, at the digital hub enterprise zone within the University of Bradford and the Centre of Skin Science; · Following the positive results of Labskin Cannabinoid (CBD) testing protocols two CBD test contracts have been signed since the beginning of the year with eight contracts currently under negotiation; · STOER For Men skin products e-commerce division, continues to be used as a control for client testing within Labskin laboratories and remains at break-even; · Staff appointments, including Paul Ryan as Head of Enterprise sales will increase major client contracts and Colin O'Sullivan as AI Architect to ramp up the IT infrastructure to accommodate digital growth across the US, EU and Asia. · Wound pHase CBD development project agreement in place for new range of medical device wound care products for chronic diabetic wounds collaboration project with Cellulac, supported by EU Interreg grants and Irish Government state supported research facility tcbb Resource. Post Year-End 2018 corporate activity: · Transformational £3m all-share Acquisition of Rinocloud Limited enabling scale-up of the business as it moves from a physical laboratory to an automated, real-time, real-world digital data platform; · Successful fundraising of £2.75m (gross); of which, o £232k was Vendor sale to allow 100% of Rinocloud to be acquired; · Additional strategic reduction of the indebtedness of the business: · Disposal of Visible Youth Group - saving £245k of future contractual liabilities; · Debt conversions - Venn £421k carried over since April 2017 IPO; · Cellulac debt conversion - £400k for hi-tech laboratory equipment; · Litigation issues settled - saving £250k of future liabilities. o Labskin York, UK laboratory increased by 40% in H1; o Investment of £400,000 for hi-tech laboratory equipment; Legacy Share Trading matters: July 2019: Venn Life Sciences (Open Orphan) 30m held in soft lock-in: Open Orphan plc (formerly Venn Life Sciences Holdings plc ("Venn-OO")), was assisted in the disposal of Venn-OO's entire holding of 30,071,428 ordinary shares, representing 3.07%, of the Company. There being high liquidity and pent up demand for large blocks of shares in the Company, the Company broker arranged for an orderly disposal of the Venn-OO shares to be placed with existing long-term shareholders, thereby eliminating any overhang on the open market. May 2019: Venn Life Sciences 42m with no lock-in: On 5 April 2019, the 2-year lock-in that Venn Life Sciences plc entered into at the Integumen IPO in April 2017, expired. An RNS issued by Venn, on the 1 May 2019, confirmed that they had disposed of 42,244,682 ordinary shares. May 2019: Enhance Skin Products Inc. 38m with no lock-in: On May 22, Enhance Skin Products Inc ("Enhance") announced the settlement of its dispute with Integumen plc., and its plan to complete its plan of reorganisation, liquidation and dissolution. At that date Enhance held 29,488,144 wit a further 8,439,072 issued in respect of the settlement agreement. Following the further distribution of shares, which were not recognised as sale or transaction, the amount of shares now held by Enhance Skin Product Inc., is now 4,905,130 and Enhance is no longer a significant shareholder as ownership has fallen below 3%. The company is now satisfied that there is no longer a large overhang of shares in this matter. Ross Andrews - Non-Executive Chairman of Integumen plc, comments: "The Company has been completely transformed over the last 12 months. The objective of disposing of non-performing subsidiaries and incorporating fully integrated teams of skilled personnel, across multiple subsidiaries, with a single focus of increasing revenue per-existing client and closing bigger deals with new clients has been met. The growth of the Company has been so well supported and received by the market that all corporate activity has been achieved, funding in place to accommodate the continued growth, and legacy share disposals from former directors and associated companies have been absorbed by the market, leaving no overhang, as we head into an exciting second half of 2019. The Board is grateful for this support and looks forward to providing you with continued updates as we progress." Interim H1 2019 results are expected to be released in early September 2019
30/7/2019
14:30
redface: Shareholders in skin have done very well this year - with a huge rise in share price...so all shareholders should be very happy! Apparently not, even after this huge increase in share price, some are ranting and unhappy...reasons - (no particular order) - Personal unresolved emotional issues Think it's gone up too much and have missed the boat Grudges against individuals in company, or on discussion board Shorting share price and trading Caring for financial well being of other investors... Maybe all, or many of the above...
26/7/2019
10:43
redface: Shareholders in skin have done very well this year - with a huge rise in share price...so all shareholders should be very happy! Apparently not, even after this huge increase in share price, some are ranting and unhappy...reasons - (no particular order) - Personal unresolved emotional issues Think it's gone up too much and have missed the boat Grudges against individuals in company, or on discussion board Shorting share price and trading Caring for financial well being of other investors... Maybe all, or none of the above...
26/7/2019
09:05
homeboy: as posted before, this is what i think the business model will be - "how its likely to pan out here - they'll put out some rns's to show progress, then they'll raise money again - dilution it'll be for some identified bolt on business probably owned by someone they know who'll do well out of being bought out. 20m skin now becomes 25m skin, but share price still near 2p thanks to the dilution, then they'll find another bolt on business and dilute again one day, skin is worth 100m, but strangely the share price is still at 2p, thanks to buying in market cap at the expense of dilutive fund raising, at a future point, skin has a 100 to 1 consolidation 2p now becomes 2 quid they then say, since we took over skin has been a major success, we built a 5m quid business into a 100m quid business, and the share price has grown to 2 quid, lol but no one makes any money except those whose businesses who were bought out. lol"
20/7/2019
10:56
homeboy: how its likely to pan out here - they'll put out some rns's to show progress, then they'll raise money again - dilution it'll be for some identified bolt on business probably owned by someone they know who'll do well out of being bought out. 20m skin now becomes 25m skin, but share price still near 2p thank to the dilution, then they'll find another bolt on business and dilute again one day, skin is worth 100m, but strangely the share price is still at 2p, thanks to buying in market cap at the expense of dilutive fund raising, at a future point, skin has a 100 to 1 consolidation 2p now becomes 2 quid they then say, since we took over skin has been a major success, we built a 5m quid business into a 100m quid business, and the share price has grown to 2 quid, lol but no one makes any money except those whose businesses who were bought out. lol
20/6/2019
10:40
tickboo: Lemming investors blog -Integumen strengthens senior sales and IT executive teamLabskin AI opens digital hub in Ireland to accommodate expansion plan across the EU and USIntegumen announces the appointment of Paul Ryan as Head of Enterprise Sales at Labskin AI. Paul has managed strategic partnering programmes and initiatives with companies such as Siemens, Microsoft, Accenture and IBM and joins the Company from 8 West Consulting, a company with more than 240 personnel, where he was Head of New Business Development. He has worked with a network of clients that include Avon, Image Skincare, Estee Lauder and Anthem Inc., a Fortune 50 US health insurer. The Company also announces the appointment of Colin O'Sullivan as Chief Information Officer (CIO). Colin is a 20-year veteran and joins the team from the Australian Medical Association where he was Group Information Officer. He brings extensive cross-platform software experience in medical and science applications ranging from enterprise applications, cloud computing, artificial intelligence, IT operations, customer experience and development operations. Over a six-year period, Colin was responsible for transforming the online business of the Australian Medical Association.Make no mistake, these appointments speak volumes as to the credibility of SKIN as a company, technology, markets, etc. These appointments should offer encouragement to investors and demonstrate the direction the company is heading. I asked CEO. Gerard Brandon about incentivising such high calibre management and aligning this with investors. In typical fashion, a straightforward no-nonsense response; "They are paid salary plus strong results orientated bonus. I am a strong believer in removing external concerns from to people so they focus on what they do best. Deliver results. If they hit their target everyone wins, big time as their share option package rises with everyone else." "The great positive on exercising of warrants are that they are cheap to access to extra working capital. No advisor fees and everyone wins when supportive shareholders can exercise "in the money" warrants. Of course, the massive liquidity in the Share means even if they were sold they would disappear in an hour of trading. So if you look back at the warrants exercised since the RinoCloud acquisition, warrant income more than covers 9 months salary if both appointees and by the time that comes around the increase in sales will address the rest. Plus hitting the targets means more sales, higher share price and these executives are well rewarded, as are Shareholders. If there are Warrants exercised "in the money" the company is doing the right things all around."Labskin AI Digital Hub IrelandFollowing the RinoCloud acquisition and integration of data management and analytic services into Labskin AI, Integumen has taken new offices in Cork, Ireland to centralise global IT operations for the Group. These state-of-the-art facilities will manage IT and further AI development, incorporating Labskin AI, the virtual laboratory-as-a-service that complements the Labskin laboratory services in York, UK and provides online customer support to clients around the world.Gerard Brandon CEO of Integumen commented:"We are delighted and fortunate to add these two exceptional individuals to the Integumen team. Under Paul's guidance, the sales team will advance the growth of Labskin AI by leveraging the existing sales, marketing and distribution channels of the Labskin laboratory services. Colin's Australian continent AI and IT operational expertise ensures Labskin AI has an architect capable of building out continent-wide bases to deliver a robust global infrastructure.Our new offices in Cork, Ireland, bring the core digital and enterprise sales teams together and are located close to many US and EU pharmaceutical corporations that fit our client target profiles. This expansion adds another exciting new chapter for Integumen."
10/5/2019
13:10
under the radar: Gerard J Brandon @gjbrandon Well it is out now. #SKIN share price put pressure to release news that offers a unique solution to medical device and clinical trials companies that have been stuck in the old testing methods for decades
13/3/2019
13:22
dynam1te: 12:15 13 Mar 2019 Integumen’s Labskin technology has been used by some of the biggest names in pharma for years, but a small tweak in how it is sold has led to a surge in sales since new boss Gerry Brandon came in Gerry Brandon has been a busy man since taking over the reins at Integumen PLC (LON:SKIN) last August. He took the job after speaking to the company’s chairman, Tony Richardson, who he grew up with in Dublin back in the 1970s. The pair would go on to work with each other at wound care specialist Alltracell Pharmaceutical, which they floated on AIM just after the turn of the millennium. Before his arrival, Integumen had been burning through the funds and debt they had secured, faster than their ability to cover costs, without much to show for it. “There were seven board members and eight members of staff when I took over,” says Brandon. “It was far from an integrated group of four companies and management had simply overlooked, or perhaps misunderstood what it was that they actually had.” What they couldn’t see was Labskin, a laboratory-grown skin that is used by cosmetics and pharmaceutical companies to see how their latest products will react to human skin. The 'Rolls-Royce of lab-grown skin' It was this piece of technology that convinced Brandon to take the top job at Integumen. “Labskin is the Rolls-Royce of laboratory-grown skin for testing, but they were selling it for the price of a Mini Cooper,” he explains to Proactive. “Every other laboratory-grown skin testing product operates in a sterile environment: In other words, you put the product on to a sterile skin. “With Labskin, we can grow bacteria on it, so we can create models for acne, eczema, psoriasis and so on. It has even been tested on Ebola.” In short, Labskin gives scientists a much better idea of how their cream or gel or make-up will react in the real world. Not only does it make animal testing redundant, the added accuracy it gives researchers reduces R&D costs by helping to improve success rates when the product is eventually taken through to Phase II clinical trials. But before he could start to make the most out of Labskin, he needed to slim the business down. Brandon ditched the loss-making oral health brand, TSpro, as well as Integumen’s Visible Youth anti-ageing products. He also trimmed the number of board members from seven to four. Now a marketing tool for cosmetic giants With the company restructured, Brandon was able to focus on growing the sales of Labskin, which were relatively small even though some of the world’s biggest companies had been using it for years. “The old management were selling it into laboratories with a restricted R&D spend,” Brandon explains. Realising the potential for Labskin to be used as a stamp of quality, he started to approach companies’ marketing decisionmakers – the ones within a business who always have more money to spend. “It was just a matter of selling it into a completely different department of the same company. “Instead of selling that proposition into companies as a test for sensitivity or allergens, we now offer the marketing department an opportunity to say, ‘our product can give you this benefit or that benefit’.̶1; As a result, clients who used to pay £2,000 for a simple test are now paying upwards of £50,000 to qualify claims about the impact of their product as an anti-ageing solution or balancing the skin’s good and bacteria. That had an immediate effect on Integumen’s top-line: Labskin revenues totalled £149,000 in the first six months of 2018, but that figure surged by almost 350% in the second half of the year. AI is the future of Labskin Brandon isn’t standing still, either. With the help of artificial intelligence firm Rinocloud, he and his team are building Labskin-on-a-chip, which will record every treatment tested on the Labskin platform and store its effects in a database. That will give every dermatology clinic with a computer, the ability to take a swab of a patient’s own skin bacteria, place it on the Labskin, run it against the database, and advise what the best course of treatment might be. Then there’s Labskin AI, a digital extension to the lab-grown skin which Brandon likens to the life science equivalent of Airbnb. It offers remote contract rental of laboratory equipment from service providers to buyers of those clinical test services, much like Airbnb matches holidaymakers with accommodation, without ever owning the house or apartment. Brandon says the combination of Labskin-on-a-chip and Labskin AI should take Integumen to the next level as it is a combination of scaling as a software rather than a physical operation only, and he is targeting 150 companies with revenue in excess of £500mln. That might sound ambitious, but Brandon reckons is far from impossible. “There are 3,685 companies that are large enough in the world to fit within that category. So, 150 is more than achievable.” The near-500% rise in the share price since his arrival would suggest that the market shares his optimism for the future.
Integumen share price data is direct from the London Stock Exchange
Your Recent History
LSE
SKIN
Integumen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191023 03:01:25